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Available online 5 February 2016Backgrounds: Bone morphogenetic protein receptor type 2 (BMPR2) signaling is anti-inﬂammatory. Decreased
BMPR2 expression was seen in lung tissue from chronic obstructive pulmonary disease (COPD) patients.
Methods: The selected single nucleotide polymorphisms (SNPs) in BMPR2 were genotyped with polymerase
chain reaction (PCR) ligase detection reaction. The effects of SNPs on gene expression were analyzed with lucif-
erase assays. The mRNA and protein expression levels of BMPR2 in peripheral blood mononuclear cells (PBMCs)
from COPD patients were determined by quantitative PCR and western blotting, respectively.
Findings: Two SNPs, rs6435156CNT and rs1048829GNT in the 3′-untranslated region (3′UTR) of BMPR2were se-
lected and genotyped in COPD case and healthy control subjects from southern Chinese population. Both of them
were found associated with signiﬁcantly increased COPD risk (adjusted odds ratio [OR] = 1.58 with 95% conﬁ-
dence interval [CI] = 1.14–2.15, P = 0.0056 for rs6435156CNT; adjusted OR = 1.47 and 95% CI = 1.10–1.97,
P=0.0092 for rs1048829GNT). Older age, cigarette smoking, family history of cancer and COPDwere all factors
that interacted with rs6435156CNT and rs1048829GNT causing increased COPD risk. Cigarette smokers with
rs6435156 (CT + TT) or rs1048829 (GT + TT) were more susceptible to COPD than that with the
rs6435156CC or rs1048829GG genotypes. In A549 human alveolar epithelial cells, luciferase reporter assays re-
vealed that introduction of 3′UTR of BMPR2 plasmids carrying rs6435156T allele but not rs1048829T led to
lower luciferase activity than the wild-type C or G alleles. Comparing to rs6435156CC, treatment with hsa-
miR-20a mimics deceased whereas hsa-miR-20a inhibitor restored the luciferase reporter activity in cells
transfected with constructs carrying rs6435156TT. BMPR2 mRNA and protein expressions were signiﬁcantly
lower in PBMCs from COPD smokers than that in non-smokers. COPD patients carrying rs6435156T allele had
less BMPR2 expression in PBMCs.
Interpretation: This study demonstrated that both rs6435156CNT and rs1048829GNT variants in BMPR2 contrib-
uted to increased susceptibility to COPD. The T variants of rs6435156 increased COPD risk likely by binding with
hsa-miR-20a, thus leading to downregulated BMPR2 expression in lung epithelial and immune cells.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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hsa-miR-20a1. Introduction
Chronic obstructive pulmonary disease (COPD), characterized by
progressive and irreversible airﬂow limitation, is a growing public
health burden and might become the third leading cause of deathspiratory Diseases, Guangzhou
Hospital, Guangzhou Medical
10120, China.
. This is an open access article underworldwide by 2020 (Raherison and Girodet, 2009). Various risk factors,
including environmental factors (mainly cigarette smoking), infection,
and genetic susceptibility are involved in the occurrence of COPD. The
lung pathology of this disease is featured by abnormal inﬂammation,
small airway wall structural remodeling, mucus hypersecretion and/or
emphysema (Rabe et al., 2007; Arinir et al., 2009). Imbalanced inﬂam-
mation and anti-inﬂammation, proteases and antiproteases, and oxida-
tion and antioxidation are thought to be the primary pathological
mechanisms underlying COPD, and abnormal inﬂammation has been
suggested to play the central role. Therefore, identifying the geneticthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Genomic structure of BMPR2 and reporter gene constructs for the 3′UTR of BMPR2.
(A) Location of the three validated SNPs (rs6435156CNT, rs1048829GNT and
rs3731696CNT) in 3′UTR of BMPR2 gene. (B) Schematic drawing of the reporter gene
constructs containing a 618 bp of 3′UTR of BMPR2 with rs6435156C or T allele, or a
620 bp of 3′UTR of BMPR2with rs1048829G or T allele.
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sis and prevention of this disease.
Bonemorphogenetic protein receptor type 2 (BMPR2), a member of
the transforming growth factor β receptor superfamily of the trans-
membrane serine/threonine kinase receptors, is expressed at high
level in various tissues including pulmonary vasculature and airway ep-
ithelium (Favre et al., 2003; Atkinson, 2002). Signaling through BMPR2
is essential for embryonic development, pulmonary vascular cell growth
and differentiation, angiogenesis, organogenesis, endothelial cell and
smooth muscle cell interaction (Shiraishi, 2012; Teichert-Kuliszewska
et al., 2006; Yang et al., 2005). Bone morphogenetic protein (BMP)
signaling pathway is not only involved in maintaining normal vascular
morphology, but also in regulating pro-inﬂammatory responses in vas-
culature (Teichert-Kuliszewska et al., 2006; Nohe et al., 2002). A recent
report by Kim et al. found that BMPR2 had unique anti-inﬂammatory
functions among BMP receptors (Kim et al., 2013). Another study
demonstrated that BMPR2 expression was decreased in lung tissue
samples from healthy smokers and COPD patients (Llinàs et al., 2011).
Yet, the exact role of BMPR2 on COPD development and progression
are unknown.
The human BMPR2 gene is located at chromosome 2q33, encoding
a 12,086 bp messenger RNA (mRNA) and 13 exons with 1038 amino
acids. BMPR2 is highly polymorphic with 3317 identiﬁed single-
nucleotide polymorphisms (SNPs) (Fig. 1A). Although BMPR2mutations
are well deﬁned to be responsible for the occurrence of majority of
heritable pulmonary arterial hypertension (PAH) and idiopathic
PAH cases (Rosenzweig et al., 2008; Sztrymf et al., 2008; Guo et al.,
2011; Wang et al., 2013; Yang et al., 2012), their relationship to
COPD has not been identiﬁed. The 3′-untranslated region (3′UTR)
of gene generally plays important roles in regulating mRNA stability,
thus affecting the translation efﬁcacy and protein expression by
interacting with other post-transcriptional regulatory factors such
as microRNAs (miRNAs). SNPs in 3′UTR could modulate the function
of 3′UTR if they are located in the binding sites for miRNAs. In this
study, we hypothesized that the presence of SNPs in 3′UTR of BMPR2
may regulate BMPR2 expression, and therefore contribute to COPD
risk by interacting with environmental factors such as cigarette
smoking. Therefore, we selected two SNPs in the 3′UTR of BMPR2,
rs6435156CNT and rs1048829GNT, genotyped them in a southern Chi-
nese population, and assessed their functional association with miRNA,
level of BMPR2 expression and risk of COPD.
2. Materials and Methods
2.1. Study Subjects
This study was conducted in 594 COPD patients and 600 age
(±5 years) and sex frequencymatched healthy control subjects of south-
ernChinese origin. All subjectswere enrolled from the First AfﬁliatedHos-
pital of Guangzhou Medical University (Guangzhou, Guangdong, China)
from January 2010 to December 2012. The COPD diagnosis was according
to the Global Initiative for Obstructive Lung Disease (GOLD) guidelines
(Rabe et al., 2007). The inclusion criteria for COPD included the following:
1) presence of chronic airway symptoms and signs, such as chronic cough,
dyspnea, sputum production, and wheezing, etc.; 2) indication of chronic
airway obstruction which was deﬁned as a forced expiratory volume in 1
(FEV1) /forced vital capacity (FVC) b 70% after inhalation of 400 μg
salbutamol. All the participants were ethnic Han Chinese and they shared
no kinship with each other. All controls were excluded if they had a his-
tory of chronic respiratory disease, atopy, an acute pulmonary infection
during the 4 weeks before assessment for participation in this study, a
family history of COPD, blood transfusion in the last 6 months, or evi-
dence of airﬂow obstruction (FEV1/FVC b 70%). All participants were
asked to provide data on smoking status, and to donate 5 ml of periph-
eral blood after an informed consent was obtained in written form. The
project was approved by the institutional review boards of GuangzhouMedical University (Ethics Committee of The First Afﬁliated Hospital
(GZMC2009-08-1336).2.2. SNP Selection
SNPs for CHB were obtained from both dbSNP and HapMap data-
bases and analyzed usingHaploview software 4.2. In this study,we orig-
inally selected three SNPs, rs6435156, rs1048829 and rs3731696,
located at the 3′UTR of BMPR2 according to the following two criteria:
(1) The minor allele frequency (MAF) N 0.05; (2) r2 threshold of 0.8,
as analyzed by a pair-wise tagging algorithm. Next, we performed link-
age disequilibrium (LD) analysis in controls and found that rs6435156
was in incomplete LDwith rs1048829 (D′=1 and r2= 0.704); in com-
plete LD with rs3731696 (D′ = 1 and r2 = 0.98), rs1048829 and
rs3731696 were in incomplete LD with each other (D′ = 0.98 and
r2 = 0.69). Therefore, we chose rs6435156 and rs1048829 to represent
all three of them for subsequent genotyping and functional analyses.2.3. Plasmid Construction
The rs6435156C allele reporter construct was prepared by amplify-
ing a 618 bp 3′UTR of human BMPR2 by using the forward primer: 5′-
CCG CTC GAG TCA CAT TGT CAA ACA GAA TTT TTC-3′ and reverse prim-
er: 5′-ATT TGC GGC CGC AAA GTC ACC AGT CTT TGC TTG G-3′. The
rs1048829G allele reporter construct was prepared by amplifying a
620 bp 3′-UTR of human BMPR2 by using the forward primer: 5′-CCG
CTC GAGATC GAGAGT TAAGATGTT TCT ATT TGA-3′ and reverse prim-
er: 5′-ATT TGC GGC CGC TGG GTT TCA AGT TGT TTT AAA AAT G-3′. The
PCR products were ligated into Psi-CHECK2 basic vector in downstream
of renilla luciferase gene at the XhoI and NotI restriction sites (Promega,
Madison, WI) to produce a BMPR2-Psi-CHECK2 reporter plasmid. The
subsequent mutation of T for rs6435156C or rs1048229G in these con-
structs was generated with the MutanBEST KIT (TaKaRa, Dalian, China)
according to the manufacturer's protocol. All constructs were se-
quenced to ensure correct sequence, orientation and integrity of each
insert (Fig. 1B). The function of the cloned fragments on upstream
Table 1
Frequency distributions of selected clinical and demographic characteristics of COPD pa-
tients and controls.
Variables Cases Controls Pa
n = 594 n = 600
n (%) n (%)
Age (years)
≤60 249 (41.91) 336 (56.00) 0.0006
N60 344 (58.01) 264 (44.00)
Sex
Male 512 (86.78) 495 (82.89) 0.1864
Female 78 (13.22) 102 (17.11)
Smoking status
Current 74 (12.54) 178 (29.82) b0.0001
Former 418 (70.85) 6 (1.01)
Neverb 98 (16.61) 413 (69.18)
Packs year
0 98 (16.59) 414 (69.46) b0.0001
0–20 80 (13.54) 122 (20.47)
20– 413 (69.88) 60 (10.07)
Passive smoke
Yes 459 (77.66) 100 (16.78) b0.0001
No 132 (22.34) 496 (83.22)
Sex and smoking
Male smokers 473 (80.00) 178 (29.87) b0.0001
Male nonsmokers 40 (6.78) 317 (53.02)
Female smokers 20 (3.38) 6 (1.01)
Female nonsmokers 58 (9.81) 96 (16.11)
Family history of cancer
Yes 8 (1.36) 6 (1.01) 0.6938
No 583 (98.64) 591 (98.99)
Family history of COPD
Yes 70 (11.86) 6 (1.01) b0.0001
No 521 (88.14) 591 (98.99)
GOLD
I 88 (14.89)
II 94 (15.91)
III 223 (37.73)
IV 186 (31.47)
Age 60.22 ± 9.91 60.61 ± 7.50 0.5974
FEV1%, predicted 42.24 ± 20.48 94.26 ± 15.69 b0.0001
FEV1/FVC, % 46.93 ± 17.67 81.41 ± 6.85 b0.0001
a P values for a two-sided χ2 test or t-test; in bold are P values b0.05.
b Individuals who had smoked fewer than 100 cigarettes in their lifetime.
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ﬂy luciferase as internal standard.
2.4. Statistical Analysis
All statistical analyses were run with SAS software (version 9.2; SAS
Institute, Cary, NC, USA), and the two-tailed P b 0.05 was considered
statistically signiﬁcant. χ2 test was used to evaluate differences in the
distributions of demographic characteristics, selected variables, and
genotypes of the variants. Goodness of ﬁt to the Hardy–Weinberg equi-
librium expectation in control was also evaluated by the χ2-test for each
SNP. Akaike's information criteria (AIC) were applied to select the most
parsimonious genetic model for each SNP (Kamikubo et al., 1986). Odds
ratios (ORs) and its corresponding 95% conﬁdence intervals (CIs) were
measured by an unconditional logistic regression model with adjust-
ment for age, sex, smoking status, and family history of cancer. Stratiﬁ-
cation analyses were also conducted by variables of interest such as age,
sex, smoking status, and family history of cancer etc. The pairwise LD
among the SNPs was calculated with Lewontin's standardized coefﬁ-
cient D′ in the publicly available Haploview 4.2 software (http://www.
broad.mit.edu/personal/jcbarret/haplo/) with default settings (the CI
for a strong LD was minimal for upper 0.98 and low 0.7 and maximal
for a strong recombination of 0.9, and a fraction of strong LD in informa-
tive comparisons was at least 0.95). LD coefﬁciency r2 and haplotype
blocks were deﬁned by the method of Gabriel et al. (2002). PHASE 2.1
Bayesian algorithmwas used to validate the haplotype frequencies esti-
mated byHaplo.stats (Stephens and Donnelly, 2003). In case ofmultiple
comparisons, the P values was adjusted in a logistic regression model
that included age, sex, smoking status, family history of cancer, and
corrected by Bonferroni test for each of the two SNPs, where P b 0.025
was considered to be signiﬁcant. For the in vitro study, the differences
between two or among multiple treatment groups were analyzed by
Student's t-test or ANOVA, respectively.
2.5. Other Methods
The procedures of genomic DNA extraction and genotyping, real-
time PCR, western blotting, RNA interferences, luciferase reporter
assay, CSE preparation and cell treatmentwere described in the supple-
mental Materials and Methods.
3. Results
3.1. Clinical and Demographical Characteristics of the Study Population
The selected clinical and demographical characteristics of the re-
cruited subjects are summarized in Table 1. Therewas no signiﬁcant de-
viation in distribution of age, sex, and family history of cancer between
the two cohorts of case and control subjects. Signiﬁcant differences in
smoking status, pack-year, passive smoking, family history of COPD,
FEV1% predicted, and FEV1/FVC% were observed between the case sub-
jects and controls (P b 0.0001). There were moremale smokers in cases
than in controls (P b 0.0001).
3.2. Association of rs6435156CNT and rs1048829GNT With COPD Risk
The genotype frequencies of the two tag SNPs (rs6435156 and
rs1048829) in the 3′UTR of BMPR2 in the study population ﬁt the
HWE (P N 0.05 for all). Multivariate logistic regression models dem-
onstrate that after adjusting for confounding factors (such as age,
sex, smoking status and family history of cancer), signiﬁcant associ-
ations were observed for the two tag SNPs (adjusted P = 0.0028 for
rs6435156 and P= 0.0030 for rs1048829 in an additive model) based
on the best ﬁt of AIC; compared with wild-type carriers in a dominant
model, a signiﬁcantly increased COPD risk was associated with the vari-
ant genotypes of rs6435156CNT (adjusted OR = 1.57 and 95% CI =1.14–2.15 for CT/TT genotypes, P=0.0056) and rs1048829GNT (adjust-
ed OR = 1.47 and 95% CI = 1.10–1.97 for GT/TT, P= 0.0092) (Table 2).3.3. Stratiﬁcation Analysis of rs6435156CNT and rs1048829GNT
Next, we next assessed the associations of the rs6435156CNT and
rs1048829GNT variant genotypes with COPD risk stratiﬁed by selected
variables listed in Table 1. As seen in Table 3, compared with the com-
mon wild-type homozygous genotype CC of rs6435156, the adverse ef-
fect of CT plus TT genotypes on COPD risk was signiﬁcant in the older
group (adjusted OR = 2.00 with 95% CI = 1.27–3.15), never-smokers
(adjusted OR = 2.47 with 95% CI = 1.50–4.09), females (adjusted
OR = 3.59 with 95% CI = 1.73–7.44), 0 pack-years of cigarette smoke
(adjusted OR=2.48with 95% CI=1.50–4.10), no family history of can-
cer (adjusted OR= 1.54 with 95% CI = 1.21–2.11), no passive smoking
subjects (adjusted OR= 2.08 with 95% CI= 1.28–3.37), without family
history of COPD (adjusted OR = 1.48 with 95% CI = 1.06–2.04), and in
those with more severe stage (GOLD IV) of COPD (adjusted OR =
1.83 with 95% CI = 1.19–2.83). Drastic interactions on COPD risk
were observed between rs6435156T variants and age (adjusted P =
4.0 × 10−4), smoking status (adjusted P = 3.8 × 10−11), pack year of
cigarette smoking (adjusted P = 1.7 × 10−14), and passive smoking
(P= 6.0 × 10−9) (Table 3). Analyses of rs1048829T variants revealed
similar results to rs6435156CNT (Table 3).
Table 2
Distribution of rs1048829GNT and rs6435156CNT genotypes and their associations with risk of COPD.
Genotypes/alleles Case Control Crude Adjusteda
(N = 594) (N = 600) OR (95% CI) OR (95% CI) P AIC
n (%) n (%)
No. of subjects 594 600
No. of alleles 1188 1200
rs1048829GNT
Co-dominant model
GG 368 (62.37) 423 (70.81) 1.00 (ref.) 1.00 (ref.) 1252
GT 192 (32.54) 158 (26.51) 1.39 (1.08–1.79) 1.37 (1.01–1.86) 0.0403
TT 30 (5.08) 16 (2.68) 2.15 (1.54–4.01) 2.58 (1.21–5.51) 0.0140
Additive model 1.42 (1.16–1.75) 1.46 (1.14–1.87) 0.0030 1249
Dominant model
GT + TT 222 (37.63) 174 (29.19) 1.46 (1.15–1.87) 1.47 (1.10–1.97) 0.0092 1251
T allele 0.21 0.16
rs6435156CNT
Co-dominant model
CC 417 (70.27) 476 (79.33) 1.00 (ref.) 1.00 (ref.) 1255
CT 158 (26.69) 118 (19.67) 1.53 (1.17–2.01) 1.49 (1.07–2.06) 0.0178
TT 18 (3.04) 6 (1.00) 3.43 (1.35–8.73) 3.32 (1.21–9.13) 0.0202
Additive model 1.61 (1.27–2.04) 1.55 (1.16–2.06) 0.0028 1253
Dominant model
CT + TT 176 (29.73) 124 (20.67) 1.62 (1.25–2.12) 1.57 (1.14–2.15) 0.0056 1254
T allele 0.16 0.11
PHWE: calculated by the Hardy–Weinberg equilibrium among the control subjects (HWE = 0.58 for rs1048829, HWE= 0.93 for rs6435156).
Power (1-β): for rs1048829 is 0.95 in additive model and 0.89 in dominant model; for rs6435156 is 0.99 in additive model and 0.96 in dominant model.
a Adjusted in a logistic regressionmodel that included age, sex, smoking status, and family history of cancer, and corrected by Bonferroni test at a signiﬁcance level of 0.05/2= 0.025 for
each of the two tested SNPs; in bold are P values b0.025.
170 J. Wang et al. / EBioMedicine 5 (2016) 167–1743.4. Effects of Haplotypes and Combined Genotypes of rs6435156CNT and
rs1048829GNT on COPD Risk
The haplotypes and combined genotypes analyses were both per-
formed to determine the separate and joint effects of rs6435156CNTTable 3
Stratiﬁcation analysis of rs1048829GNT and rs6435156CNT on COPD risk.
Variables rs1048829GNT
Casea Controla OR (95%CI)b A
GG\GT + TT GG\GT + TT
Age 7
≤60 156/92 240/94 1.48 (0.97–2.26)
N60 212/130 183/80 1.45 (0.97–2.17)
Sex 0
Male 324/188 348/146 1.27 (0.91–1.76)
Female 88/34 75/28 2.57 (1.32–5.01)
Smoking status 3
Yes 314/178 126/58 1.21 (0.84–1.74)
No 54/44 297/116 1.96 (1.22–3.16)
Pack year 1
20– 260/152 32/28 0.66 (0.38–1.14)
0–20 54/26 92/30 1.57 (0.83–3.00)
0 54/44 299/116 1.97 (1.22–3.18)
Passive smoke 1
Yes 284/174 64/36 1.16 (0.72–1.88)
No 84/48 359/138 1.55 (0.98–2.43)
Family history of cancer 0
Yes 4/4 6/2 1.11 (0.87–1.37)
No 364/218 417/174 1.45 (1.08–1.94)
Family history of COPD 0
Yes 40/30 8/4 1.04 (0.79–1.26)
No 328/192 415/170 1.42 (1.05–1.92)
GOLD −
I 54/34 423/174 1.53 (0.94–2.51)
II 60/34 423/174 1.33 (0.80–2.23)
III 156/66 423/174 0.99 (0.67–1.46)
IV 98/88 423/174 2.15 (1.43–3.25)
a Dominant model: Wild homozygote \ Heterozygote + Variant homozygote.
b Adjusted in a logistic regressionmodel that included age, sex, smoking status, and family hi
bold are P values b0.025.
c P value: calculated by gene–environment interaction.and rs1048829GNT on COPD risk (Table 4). Compared to the major
common haplotype G-C, the haplotype T–T of rs6435156 and
rs1048829 showed signiﬁcant association with increased COPD risk
(adjusted OR = 1.25, 95% CI = 1.08–1.44 and P = 0.002) (Table 4).
In combined genotypes risk analysis, we found that the presence ofrs6435156CNT
djusted Pc Casea Controla OR (95%CI)b Adjusted Pc
CC\CT + TT CC\CT + TT
.9 × 10−3 4.0 × 10−4
175/75 264/70 1.28 (0.82–2.02)
242/101 212/54 2.00 (1.27–3.15)
.05 0.01
366/148 392/104 1.25 (0.88–1.79)
100/56 84/20 3.59 (1.73–7.44)
.7 × 10−18 3.8 × 10−11
356/138 138/44 1.12 (0.76–1.66)
60/38 338/78 2.47 (1.50–4.09)
.4 × 10−21 1.7 × 10−14
299/115 40/20 0.74 (0.41–1.32)
58/23 98/24 1.39 (0.70–2.73)
60/38 340/78 2.48 (1.50–4.10)
.6 × 10−14 6.0 × 10−9
326/134 72/28 1.02 (0.61–1.69)
80/42 404/94 2.08 (1.28–3.37)
.98 0.98
4/4 10/4 1.17 (0.93–1.52)
413/172 466/120 1.54 (1.12–2.11)
.97 0.97
22/13 41,279 1.06 (0.87–1.18)
186/75 234/60 1.48 (1.06–2.04)
−
60/28 476/121 1.74 (0.89–3.12)
68/26 476/121 1.36 (0.78–2.38)
168/54 476/121 1.08 (0.71–1.64)
120/68 476/123 1.83 (1.19–2.83)
story of cancer, and corrected by Bonferroni test at a signiﬁcance level of 0.05/2= 0.025; in
Fig. 2. Luciferase activity of the constructed plasmids in A549 cells. Constructs containing
rs6435156C or T allele (A) or rs1048829G or T allele (B) were transfected into A549 cells
and the luciferase activity was measured. The renilla luciferase activity of each construct
was normalized against the activity of ﬁreﬂy luciferase. Data were from three triplicate
experiments and shown as mean ± SD. (**P b 0.01).
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“1”) did not cause signiﬁcant inﬂuence on COPD risk; however, com-
pared to “0” variants, therewas a signiﬁcantly increased risk of COPD as
the number of risk genotypes T increased to “2” (adjusted OR = 1.26,
95% CI = 1.10–1.48 and P= 0.005), indicating that these variants had
a joint effect on the risk of COPD (adjusted trend test P = 0.0012)
(Table 4). Nevertheless, compared with rs1048829GNT (P = 0.926),
rs6435156CNT took the main effect (P = 0.043) on COPD risk, as re-
vealed by regression analysis when two of them were included in the
same regression model.
3.5. Effects of rs6435156 and rs1048829 Polymorphisms on BMPR2 Gene
Reporter Activity
To determine the effects of the rs6435156CNT and rs1048829GNT
polymorphisms on BMPR2 expression, four constructs with a fragment
of BMPR2 3′UTR carrying rs6435156C or T, rs1048829G or T ligated in
downstreamof a luciferase reporter genewere generated and transfected
into A549 cells. As shown in Fig. 2A, the transcription activity of the re-
porter gene in cells carrying rs6435156T allele was drastically lower
than that those carrying C allele (P= 6.7 × 10−6 for rs6435156T versus
C), suggesting that the T variant of rs6435156 negatively modulated
BMPR2 expression in A549 cells. However, the luciferase reporter activity
was not different between cells transfected with vector carrying
rs1048829T and G allele (Fig. 2B).
3.6. Effects of rs6435156CNT Genotypes on BMPR2 Expression in PBMCs
From COPD Subjects
In order to determine the inﬂuence of rs6435156CNT polymorphism
on BMPR2 expression in COPD patients, we assessed the levels of BMPR2
mRNA and protein in PBMCs from COPD patients carrying CC, CT or TT
genotype of rs6435156. The CT carriers exhibited signiﬁcant reduced
mRNAand protein expression of BMPR2 comparingwith the CC carriers.
The level of BMPR2mRNA and protein expression was further reduced
in PBMCs from COPD subjects with rs6435156TT genotype compared
to CT (Fig. 3).
3.7. Synergistic Effects of rs6435156T Variants and Cigarette Smoking on
BMPR2 Expression
Considering that cigarette smoking is a pivotal risk factor in COPD
pathogenesis, we investigated the rs6435156 polymorphism distri-
bution in smoking and non-smoking COPD patients. As shown in
Fig. 4A–C, cigarette smoking induced greater decreases of BMPR2
mRNA and protein level in PBMCs from COPD smokers than from
non-smokers,with further reduction in those smoking patients carrying
rs6435156CT genotype. Due to limited sample size available, we didn'tTable 4
Effect of haplotypes and combined genotypes of rs1048829GNT and rs6435156CNT on COPD r
Genotypes Cases Controls
n (%) n (%)
No. of subjects 594 600
No. of haplotypes 1188 1200
Haplotypesb
G-C 928 (48.08) 1001 (51.92)
T-C 58 (49.15) 60 (50.85)
T–T 194 (59.88) 130 (40.12)
Risk genotypesc
0 368 (46.58) 421 (53.42)
1 46 (47.92) 50 (52.08)
2 175 (58.67) 124 (41.33)
Trend test P value
a Adjusted in a logistic regression model that included age, sex, smoking status, and family h
b Haplotype constructed with order of SNPs: rs1048829GNT and rs6435156CNT of BMPR2;
c Genotype combinations in BMPR2: rs1048829T variant genotypes GT and TT and rs643515evaluate the association of BMPR2 expression level and genotype
rs6435156TT under cigarette smoking. According to these results, we
hypothesize that rs6435156CNT polymorphism is associated with
BMPR2 expression reduction in COPD patients, especially in those with
cigarette smoking history.
To further verify the association between rs6435156CNT and ciga-
rette smoking on modulating BMPR2 expression, A549 cells were
transfected with the luciferase reporter construct carrying rs6435156C
or T genotype and then treated with 5% CSE for 72 h. CSE signiﬁ-
cantly reduced the luciferase activity in cells carrying rs6435156C
or T constructs; however, the more obvious reduction of luciferase
activity was observed in cells carrying T construct (P = 6.7 × 10−5)
(Fig. 4D). This result suggests that rs6435156T variant potentiated
cigarette smoking induced BMPR2 downregulation in pulmonary
epithelial cells.
3.8. Effects of miR-20a on BMPR2 Expression
The 3′UTR of genes generally functions by binding with microRNA
and therefore modulate mRNA stability and gene expression. We
subjected the sequence of rs6435156 to a bioinformatics analysis
(http://snpinfo.nih.gov/) and found that rs6435156 located at the
potential binding site of has-miR-20a (Fig. 5A). The reporter con-
structs rs6435156CC or TT was transfected into A549 cells with co-
transfection of miR-20a mimics or inhibitor. When compared with
cells without co-transfection, the mimics of miR-20a could suppress
the mRNA expression of BMPR2 gene in A549 cells with rs643515TT
genotype. However, the reduction of luciferase activity could be re-
covered by co-transfected hsa-miR-20a inhibitors in both cellsisk.
Crude Adjusted
OR (95%CI) OR (95%CI)b Pa
1.00 (ref.) 1.00 (ref.)
1.04 (0.72–1.51) 1.24 (0.79–1.97) 0.352
1.27 (1.13–1.43) 1.25 (1.08–1.44) 0.002
1.00 (ref.) 1.00 (ref.)
1.06 (0.69–1.61) 1.16 (0.69–1.97) 0.577
1.28 (1.12–1.46) 1.26 (1.10–1.48) 0.005
0.0006 0.0012
istory of cancer.
if frequency of haplotype is below 0.05, then delete such as G-T.
6T variant genotypes CT and TT are deﬁned as risk genotypes.
Fig. 3. BMPR2 expression levels in PBMCs from COPD patients carrying SNP
rs6435156CNT. (A) BMPR2 mRNA levels were determined by quantitative RT-PCR with
18s rRNA as internal control. (Individual rs6435156CNT genotype: CC, n = 18; CT, n =
20; TT, n = 4). (B) BMPR2 protein levels in PBMCs carrying rs6435156CNT genotype
were detected by western blotting. The level of β-actin was taken as internal control.
Data were randomly selected from 44 individuals detected in one experiment (CC, n =
18; CT, n = 20; TT, n = 4). (C) Relative protein expression level by rs6435156CNT
genotype was calculated in 44 individuals via band intensity quantiﬁcation and
normalization to internal control β-actin. Data were shown as mean ± SD and analyzed
with Student's t-test.
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gested miR-20a target to rs6435156 in 3′UTR of BMPR2 mRNA and
lead to decreased BMPR2 expression. The rs6435156T variant poten-
tiates the binding of miR-20a to this site, which results in greater
downregulation of BMPR2.
4. Discussion
The present study demonstrated that both rs6435156CNT and
rs1048829GNT variant genotypes in the 3′UTR of BMPR2 wereassociated with increased risk of COPD in a southern Chinese popula-
tion. COPD smokers carrying the T variant (CT and TT) of rs6435156 ex-
hibited signiﬁcantly reducedmRNA and protein expression of BMPR2 in
PBMCs comparing with the CC carrier smokers. Moreover, we found
that the rs6435156T variants signiﬁcantly decreased the expression of
BMPR2 both alone and in synergy with cigarette smoke exposure in
lung epithelial cells. The miRNA hsa-miR-20a was responsible for de-
creased expression of BMPR2 in cells carrying rs6435156T genotype.
Reduction of BMPR2 expression was observed in the lung tissue
of COPD patients (Llinàs et al., 2011). However, none has been
known about the association between BMPR2 mutation and COPD.
As an identiﬁed risk factor, BMPR2 gene mutations have been
shown to be related with the occurrence of heritable and idiopathic
PAH. Deﬁciency of BMPR2 induced more obvious perivascular in-
ﬂammation and muscularization characterized by increased thick-
ness of small pulmonary arterioles in BMPR2 mutants than in wild
type mice with pulmonary hypertension (PH) (Song et al., 2008).
Though PH is a common comorbidity of COPD, BMPR2 gene mutation
has not been assessed as a risk factor for COPD. This may be due to
the complex nature of COPD pathology, which has been recognized
to involve interactions of multiple genes and environment factors.
In this study, we identiﬁed that both rs6435156CNT and
rs1048829GNT in 3′UTR of BMPR2 were signiﬁcantly associated
with increased COPD risk, when analyzed separately and in a joint
manner. However, it was rs6435156T, but not rs1048829T variant
found being associated with decreased BMPR2 expression in lung
epithelial cells when assessed by luciferase reporter assay. The fact
that both rs6435156T and rs1048829T variants were signiﬁcant
when included in the same regression model further suggests that
the association of rs1048829 with COPD is not due to the LD with
rs6435156. The apparent discrepancy between the above population
study and in vitro functional study is likely due to the effects of
rs1048829GNT on COPD risk is not strong enough to be monitored
in our tested in vitro system. Consistently, we found rs6435156CNT
took the main effect on COPD risk comparing to rs1048829GNT
when regression analysis was performed with two of the SNPs in-
cluded in the same regression model. In addition, it is also likely
that rs1048829GNT functions by affecting rs6435156CNT, thus pre-
senting a joint effect on COPD risk; yet, this assumption needs to be
further investigated in the future study.
In this study, we showed that rs6435156T variant genotype is asso-
ciated with reduced BMPR2 expression in PBMCs from COPD non-
smokers and with further reduction in COPD smokers. Moreover, con-
sistent with these results from the in vivo study, we found that, al-
though CSE decreased the luciferase reporter activity in cells carrying
rs6435156C, it caused greater decrease of the reporter activity in cells
carrying rs6435156T variant (Fig. 4D). According to bioinformatics anal-
ysis, we found the rs6435156CNT resides in the potential binding site of
has-miR-20a. MicroRNAmiR-20a was shown to regulate BMP signaling
pathway through targeting on the binding sites of 3′UTR of BMP-2 and
possibly BMPR2 gene in ﬁsh skeletogenesis (Tiago et al., 2014). Treat-
ment of antagomiR-20a restored the functional levels of BMPR2 expres-
sion in pulmonary arteries (Brock et al., 2014). Interestingly, we found
treatment of miR-20a mimics increased, and miR-20a inhibitor de-
creased the luciferase activity in cells carrying rs6435156TT variants.
In contrast, both miR-20a mimics and inhibitor did not change the
level of luciferase activity in cells carrying rs6435156CC genotypes.
These results indicate that cigarette smoke normally could downregu-
late BMPR2 expression independent of has-miR-20a; however, under
the presence of rs6435156T variant, it further decreases BMPR2 ex-
pression in has-miR-20a dependent manner; the rs6435156CNTmu-
tation is responsible for downregulated BMPR2 expression likely by
recruiting the binding of miR-20a to the 3′UTR of BMPR2. Consistent-
ly, Brock M. et al. identiﬁed that expression of BMPR2was modulated
by a STAT3-miR-17/92-BMPR2 pathway, in which miRNA cluster 17/92
(miR-17/92) encodes hsa-miR-20a. A highly conserved STAT3-binding
Fig. 5. Association of has-miR-20a and BMPR2 gene expression. (A) Proposed binding of
has-miR-20a to 3′UTR of BMPR2. The SNP rs6435156CNT is located within the seed
region of the binding site with the T allele perfectly matching the corresponding C allele
in miR-20a. (B) Luciferase activity in A549 cells carrying rs6435156C or T allele under
co-transfection of miR-20a mimics or miR-20a inhibitors. Data were mean of three
triplicate experiments and shown as Mean ± SD.
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ated IL-6 modulated BMPR2 expression (Brock et al., 2009). As a proin-
ﬂammatory factor, IL-6 was upregulated by cigarette smoking in lung
tissue from COPD patients (Llinas et al., 2011). Plasma IL-6 level was
suggested to be a persistent and progressive parameter in evaluating
systemic inﬂammatory process and mortality association in COPD pa-
tients (Ferrari et al., 2013). Based on the above evidence from us and
others, we propose that the higher risk of COPD in cigarette smoking
populations carrying rs6435156T variant is likely due to IL-6 and hsa-
miR-20a mediated downregulation of BMPR2 expression.
Given that A549 cells we used are not derived from the small air-
ways but are a transformed cell line with a pneumocyte phenotype,
and our BMPR2 protein and mRNA expression work was performed in
PBMCs but not lung tissue, we performed eQTL look-up in lung cell
types (including whole human lung) to see whether or not the studied
SNPs rs6435156CNT and rs1048829GNT indeed act as cis acting eQTLs
for BMPR2. Based on calculation in the online free resources of SNPexp
and GENE Expression VARiation (Genevar), only rs1048829 was found
to act as cis acting eQTLs for BMPR2 thoughwith weak statistical differ-
ence (P=0.05). The possible reason for the conﬂicting results between
eQTL results and the functional results we obtained in this study might
be due to the bank data in SNPexp was not derived from Chinese popu-
lation and Genevar was not from COPD patients (Cheung et al., 2012;
Holm et al., 2010; Yang et al., 2010).
It is generally believed that the initial event in the natural history of
PH associated with COPD could be due to endothelial dysfunction and
inﬂammation caused by risk factors including cigarette smoke
(Barbera and Blanco, 2009). Although the actual role of BMPR2 in PH
or COPD development are not fully understood, it was known playing
an anti-inﬂammatory function in endothelial cells in response to
proatherogenic stimuli (Kim et al., 2013). In BMPR2 heterozygous mu-
tant mice, BMPR2 deﬁciency leads to enhanced proinﬂammatory cyto-
kine production in pulmonary artery smooth muscle cells (Davies
et al., 2012). BMP4, a ligand of BMPR2, participates in controllingFig. 4. Effects of SNP rs6435156CNT on BMPR2 expression under cigarette smoke
exposure. The mRNA and protein level of BMPR2 were determined in PBMCs from 38
COPD patients with rs6435156CNT genotype (CC, non-smoker = 9, smoker = 9; CT,
non-smoker = 10, smoker = 10). (A) Relative mRNA level was determined by
quantitative RT-PCR. (B) The BMPR2 protein levels with β-actin as internal control. Data
were randomly selected from the 38 individuals. (C) Relative protein expression level by
rs6435156CNT genotype was calculated in 38 individuals via band intensity
quantiﬁcation and normalization to internal control β-actin. Data were shown as
mean ± SD and analyzed with Student's t-test. (D) A549 cells were transfected with
luciferase reporter constructs containing rs6435156C or T allele and subjected to culture
with cigarette smoke extract (CSE, 5%). The relative luciferase activity was measured.
Data were from three triplicate experiments and shown as mean ± SD. (**P b 0.01).
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2014). Collectively, these evidence suggest that BMPR2 could be a
critical anti-inﬂammatory factor in the lung, where the mutation of
BMPR2 contributes to uncontrolled inﬂammation and development
of COPD. Considering both genetic and environmental factors were
involved in COPD pathology, we further tested the interaction be-
tween BMPR2 mutation and cigarette smoking on COPD risk. Our re-
sults from both population-based in vivo and cell-based in vitro study
conﬁrmed that the rs6435156CNTmutation in 3′UTR of BMPR2 contrib-
uted to downregulated BMPR2 expression in epithelial and immune
cells, at least in part by interacting with cigarette smoke-induced ef-
fects. The ﬁndings of our study are limited by hospital-based case–con-
trol population in southern Chinese. Larger population-based studies in
different ethnic groups are warranted for future validation. In addition,
this study is also limited by SNP assessment in the 3′UTR of BMPR2, the
roles of SNPs or other types of mutations in other regions of BMPR2
gene, i.e. the promoter, the coding exons and introns, etc., worth further
investigating to fully understand the relationship of BMPR2 mutation
and COPD risk.
In summary, this study demonstrated that the functional polymor-
phism rs6435156CNT in the 3′UTR of BMPR2 contributes to increased
risk of COPD likely via bindingwith has-miR-20a. The rs6435156T geno-
type of BMPR2may serve as an important target for novel drug develop-
ment and as a biomarker for COPD susceptibility assessment.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ebiom.2016.02.004.
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